Characterization of baseline and treatment-emergent resistance to T-20 (enfuvirtide) observed in Phase II clinical trials: substitutions in gp41 amino acids 36-45 and enfuvirtide susceptibility of virus isolates
ANTIVIRAL THERAPY（2002）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要